Expert Insight View All

The potential new first-line mNSCLC treatment regardless of PD-L1: Durvalumab + tremelimumab + chemotherapy improved survival

Over the past decades, treatment options in advanced non-small cell lung cancer (NSCLC) patients without oncogenic drivers have been limited to cytotoxic chemotherapies with poor survival outcomes.1 Although patients’ overall survival (OS) has been prolonged with the current standard of care (SoC) (i.e. pembrolizumab with or without chemotherapy) in recent years, the clinical outcomes are still suboptimal.2,3 Dual immunotherapy, which brought substantial survival improvements across multiple malignancies such as advanced melanoma, sheds light on the further advance of metastatic NSCLC (without driver mutations) management.4 The combination of nivolumab (NIVO) and ipilimumab (IPI) with or without chemotherapy has demonstrated superior survival benefits in these patients, leading to the regulatory approval from the United States (US) Food and Drug Administration (FDA).5,6 More recently, the efficacy of durvalumab and tremelimumab plus chemotherapy (D + T + CT) in treatment-naïve metastatic NSCLC patients has also been evaluated in the POSEIDON trial.7 In a webinar organized by the Hong Kong Precision Oncology Society, Dr. Melissa L. Johnson presented the encouraging data from POSEIDON and discussed the latest advances of immunotherapy in metastatic NSCLC. Dr. Au, Siu-Kie Joseph also shared his expert insights on the new POSEIDON data and discussed their impacts on the local clinical practice in an interview with Omnihealth Practice.

03 May 2022

Dr. Melissa L. Johnson

Lung Cancer Research Program,
Sarah Cannon/Tennessee Oncology PLLC,
Nashville, United States


Dr. Au, Siu-Kie Joseph

Head and Consultant Clinical Oncologist,
Hong Kong Adventist Hospital Oncology Centre
Hong Kong Lung Cancer Study Group
Hong Kong Precision Oncology Society

Conference Update View All
Meeting Highlight View All

Adopting durvalumab consolidation therapy: A breakthough for non-small cell lung cancer treatment


Dr. Lee, Ho-Fun Victor

Clinical Associate Professor,
Department of Clinical Oncology,
The University of Hong Kong


Dr. Chan, Siu-Hong Oscar

Specialist in Clinical Oncology,
Hong Kong Integrated Oncology Centre


Dr. Nyaw, Shi-Feng Jonathan

Specialist in Clinical Oncology,
Department of Clinical Oncology,
Tuen Mun Hospital

News & Perspective View All

AI-created digital twins of vertebra predict the vertebral fracture risk IN SM patients

It is projected that there will be 1.9 million new cancer diagnoses and over 600,000 cancer deaths in 2022 in the United States alone.1 Spine is the most common site for bone metastasis; up to 70% of cancer patients could experience spinal metastasis (SM) and about 20% of them become symptomatic, causing considerable pain and morbidity.2 Most common regions for SM are dorsal (45%), lumbar (17%), cervical (14%), and dorsolumbar (10%).3 Vertebral fractures (VFs) are the common complications of SM, with an estimation of 30% of patients developing VFs that mostly require surgery.4 Tumor lesions and some treatments for cancer can lead to loss of bone tissue, thus increasing the risk of VFs.5 Hence, it is imperative to predict the VF risk in SM patients, so that well-informed interventions can be designed.5 Factors influencing VFs include both the macro- and micro-structure of the vertebra, especially of the trabecula.5 In-vitro methods are used to study the biomechanical forces that alter the vertebral shape, but they cannot accurately measure in-vivo stresses that damage its microstructure.5 The development of computational modeling has made it a compelling tool for measuring these in-vivo stressors.5 A recent study by Ahmadian et al was to assess the feasibility of the artificial intelligence (AI)-assisted framework to create ‘digital twins’ of the human vertebra, termed ReconGAN, to predict the VF risk in both osteolytic and osteoblastic metastatic tumors.5

08 Jul 2022
Infographics View All

Fiber-rich diet associated with better response to immunotherapy in patients with melanoma

25 Feb 2022